Literature DB >> 1759495

Controlled release microparticles for vaccine development.

D T O'Hagan1, H Jeffery, M J Roberts, J P McGee, S S Davis.   

Abstract

The primary and secondary sera IgG antibody responses to ovalbumin (OVA) entrapped in biodegradable poly(lactide-co-glycolide) (PLGA) microparticles were compared with the responses obtained with soluble OVA. In addition, OVA in PLGA microparticles was also administered after dispersion in an immunostimulatory vehicle, Freund's incomplete adjuvant (FIA). The primary IgG responses to OVA in microparticles/FIA were significantly greater than the responses to soluble OVA from day 14 to day 42, when booster immunizations were administered. From day 49 to the end of the study at day 84, the responses to OVA, both in microparticles alone and in microparticles/FIA, were significantly greater than the responses to soluble OVA. Nevertheless, the responses obtained for OVA in microparticles or microparticles/FIA were, in general, not as high as those obtained with OVA in Freund's complete adjuvant.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1759495     DOI： 10.1016/0264-410x(91)90295-h

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.

Authors:  S J Challacombe; D Rahman; H Jeffery; S S Davis; D T O'Hagan
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

3.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 4.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

Review 5.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpes virus type-1 mediates immunosuppression in the horse.

Authors:  S Charan; K Palmer; P Chester; A R Mire-Sluis; A Meager; N Edington
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 7.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

8.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique.

Authors:  H Jeffery; S S Davis; D T O'Hagan
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

10.  Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity.

Authors:  A E Gregory; E D Williamson; J L Prior; W A Butcher; I J Thompson; A M Shaw; R W Titball
Journal:  Vaccine       Date:  2012-09-18       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.